Evidence map›Paper›PMID 34535185›Full record

ArticleClinical epigenetics2021

Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance.

Jingwei Li, Kun Fang, Lavanya Choppavarapu, Ke Yang, Yini Yang, Junbai Wang, Ruifeng Cao, Ismail Jatoi, Victor X Jin

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.Cellular oncology (Dordrecht, Netherlands) · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Exploration of targeted anti-tumor therapy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Jingwei Li *Department of Gastrointestinal Surgery, The Third Xiangya Hospital, Central South University, Changsha, 410006, Hunan, People's Republic of China.
Kun Fang *Program of Biomedical Engineering, UTHSA-UTSA Joint Graduate Program, San Antonio, TX, 78229, USA.
Lavanya Choppavarapu *Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Ke Yang *Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Yini YangDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Junbai WangDepartment of Pathology, Oslo University Hospital - Norwegian Radium Hospital, 0310, Montebello, Oslo, Norway.
Ruifeng CaoDepartment of Biomedical Sciences, University of Minnesota Medical School, Duluth, MN, 55812, USA.
Ismail JatoiDepartment of Surgery, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Victor X JinDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA. jinv@uthscsa.edu.ORCID 0000-0002-8765-3471
Central South University · CNThe University of Texas Health Science Center at San Antonio · USOslo University Hospital · NOUniversity of Minnesota, Duluth · US

Funding

Systems Analysis of Epigenomic Architecture in Cancer ProgressionU54CA217297 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2017 to 2021
$9.3M
Omics analysis of three-dimensional transcriptional regulationR01GM114142 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JIN, VICTOR, LIN, SHILI · 2015 to 2024
$2.7M
Mammalian target of rapamycin signaling and the suprachiasmatic circadian clockR01NS118026 · NINDS · UNIVERSITY OF MINNESOTA · PI CAO, RUIFENG (RAY) · 2020 to 2024
$1.8M
NCI NIH HHS U54 CA217297NIGMS NIH HHS R01 GM114142NINDS NIH HHS R01 NS118026
6 · The paper itself

Abstract

backgroundOrganoids or spheroids have emerged as a physiologically relevant in vitro preclinical model to study patient-specific diseases. A recent study used spheroids of MCF10 cells to model breast cancer progression and identified targetable alterations more similar to those in vivo. Thus, it is practical and essential to explore and characterize the spheroids of the commonly used human breast cancer (BC) cells.

methodsIn this study, we conducted Hi-C analyses in three-dimensional (3D) spheroids of MCF10A, MCF7 and MCF7TR cells and compared TADs and looping genes with those in 2D monolayers. Furthermore, we performed in silico functional analysis on 3D-growth-specific looping genes and to compare patient outcomes with or without endocrinal therapy. Finally, we performed 3C/RT-qPCR validations in 3D spheroids and 3D-FISH confirmations in organoids of breast cancer patient tissues.

resultsWe found that chromatin structures have experienced drastic changes during the 3D culture growth of BC cells although there is not much change in the quantity of chromatin domains. We also observed that the strengths of looping genes were statistically different between 2D monolayers and 3D spheroids. We further identified novel 3D growth-specific looping genes within Hippo relevant pathways, of which two genes showed potential prognostic values in measuring the outcome of the endocrine treatment. We finally confirmed a few selected genes in Hippo relevant pathways with enhanced looping in organoids of breast cancer patient tissues.

conclusionsHence, our work has provided significant insights into our understanding of 3D-growth-specific chromatin architecture in tamoxifen-resistant breast cancer. Our analyses suggest that the strengthened looping-mediated Hippo relevant pathways may contribute to endocrine therapy resistance in breast cancer patients.

Indexed as

AdultBreast NeoplasmsChromatinDNA MethylationEndocrine DisruptorsFemaleHumansMiddle AgedSpheroids, CellularChromatinEndocrine Disruptors3D spheroidsHi-CLooping genesOrganoidsTamoxifen-resistant breast cancer

Identifiers

PMID34535185
PMCPMC8447690
OpenAlexW3201317092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.